Cabaletta Bio (CABA) – Research Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Cabaletta Bio (NASDAQ: CABA):

  • 1/8/2021 – Cabaletta Bio had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $21.00 price target on the stock.
  • 1/4/2021 – Cabaletta Bio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 12/28/2020 – Cabaletta Bio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 12/22/2020 – Cabaletta Bio was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 12/21/2020 – Cabaletta Bio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 12/18/2020 – Cabaletta Bio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 12/10/2020 – Cabaletta Bio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 12/8/2020 – Cabaletta Bio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $18.00 price target on the stock. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 12/7/2020 – Cabaletta Bio was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 12/3/2020 – Cabaletta Bio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 11/30/2020 – Cabaletta Bio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $17.00 price target on the stock. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 11/26/2020 – Cabaletta Bio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “
  • 11/13/2020 – Cabaletta Bio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. “

Cabaletta Bio stock traded up $1.54 during mid-day trading on Friday, reaching $14.61. 805 shares of the company traded hands, compared to its average volume of 126,342. Cabaletta Bio, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $19.63. The company has a market capitalization of $351.52 million, a price-to-earnings ratio of -10.66 and a beta of 1.67. The firm’s fifty day moving average is $13.89 and its two-hundred day moving average is $12.10.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Sunday, November 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.08. Research analysts anticipate that Cabaletta Bio, Inc. will post -1.38 EPS for the current year.

In other Cabaletta Bio news, major shareholder Ventures V. L.P. 5Am sold 298,000 shares of the company’s stock in a transaction that occurred on Thursday, December 10th. The shares were sold at an average price of $14.75, for a total transaction of $4,395,500.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.51% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in shares of Cabaletta Bio by 99.3% in the second quarter. Bank of America Corp DE now owns 6,659 shares of the company’s stock worth $75,000 after acquiring an additional 3,317 shares during the period. American International Group Inc. increased its stake in shares of Cabaletta Bio by 100.6% in the second quarter. American International Group Inc. now owns 7,896 shares of the company’s stock worth $88,000 after acquiring an additional 3,960 shares during the period. PDT Partners LLC acquired a new stake in shares of Cabaletta Bio in the second quarter worth $142,000. New York State Common Retirement Fund increased its stake in shares of Cabaletta Bio by 355.2% in the second quarter. New York State Common Retirement Fund now owns 13,200 shares of the company’s stock worth $147,000 after acquiring an additional 10,300 shares during the period. Finally, Two Sigma Advisers LP acquired a new stake in shares of Cabaletta Bio in the second quarter worth $189,000. Hedge funds and other institutional investors own 68.00% of the company’s stock.

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.

Featured Story: How mutual funds make money

Receive News & Ratings for Cabaletta Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.